Globus Medical
GMED · Health Care Equipment
$81.41
0.3%Revvity
RVTY · Health Care Equipment
$158.77
0.9%The short version
- Globus Medical is the larger business, with $2.9B of revenue in fiscal 2025 against $2.9B for Revvity.
- Globus Medical grew revenue faster (16.7%, against 3.7%).
- Globus Medical kept more of each dollar of sales as operating profit (16.3% operating margin, against 12.5% operating margin).
- Globus Medical turned more of its sales into free cash flow (20.0% FCF margin, against 17.8% FCF margin).
- Globus Medical earned a higher return on the capital invested in it (11.0%, against 3.3%).
- Investors pay more for each dollar of Revvity’s earnings: a P/E of 76.0x against 20.9x for Globus Medical.
| Latest fiscal year | GMED · FY25 | RVTY · FY25 |
|---|---|---|
| Size | ||
| Market cap | $11.2B | $17.7B |
| Revenue | $2.9B | $2.9B |
| Free cash flow | $589M | $509M |
| Net income | $538M | $241M |
| Growth | ||
| Revenue growth | 16.7% | 3.7% |
| 5-year growth | 30.1% | −5.5% |
| Share count change | −0.6% | −5.1% |
| Profitability | ||
| Gross margin | 67.4% | — |
| Operating margin | 16.3% | 12.5% |
| Net margin | 18.3% | 8.5% |
| FCF margin | 20.0% | 17.8% |
| Return on capital | 11.0% | 3.3% |
| Return on equity | 12.3% | 3.2% |
| Balance sheet | ||
| Net debt | −$556M | $2.3B |
| Net debt / EBITDA | −0.7x | 3.0x |
| Dividends and buybacks | $301M | $854M |
| Valuation & quality | ||
| P/E | 20.9x | 76.0x |
| Piotroski F-score | 9 | 5 |
FY16
GMED $564M
RVTY $2.1B
FY17
GMED $636M
RVTY $2.3B
FY18
GMED $713M
RVTY $2.8B
FY19
GMED $785M
RVTY $2.9B
FY20
GMED $789M
RVTY $3.8B
FY21
GMED $958M
RVTY $3.8B
FY22
GMED $1.0B
RVTY $3.3B
FY23
GMED $1.6B
RVTY $2.8B
FY24
GMED $2.5B
RVTY $2.8B
FY25
GMED $2.9B
RVTY $2.9B
GMED
RVTY
FY16
GMED 27.3%
RVTY 13.9%
FY17
GMED 25.5%
RVTY 13.1%
FY18
GMED 23.8%
RVTY 11.7%
FY19
GMED 21.9%
RVTY 12.6%
FY20
GMED 14.1%
RVTY 22.9%
FY21
GMED 18.0%
RVTY 32.9%
FY22
GMED 22.3%
RVTY 22.4%
FY23
GMED 8.5%
RVTY 10.9%
FY24
GMED 6.6%
RVTY 12.6%
FY25
GMED 16.3%
RVTY 12.5%
GMED
RVTY
FY16
GMED $107M
RVTY $319M
FY17
GMED $108M
RVTY $249M
FY18
GMED $122M
RVTY $218M
FY19
GMED $101M
RVTY $287M
FY20
GMED $135M
RVTY $829M
FY21
GMED $219M
RVTY $1.3B
FY22
GMED $104M
RVTY $594M
FY23
GMED $165M
RVTY $9.9M
FY24
GMED $405M
RVTY $542M
FY25
GMED $589M
RVTY $509M
GMED
RVTY
FY16
GMED 14.4%
RVTY 9.1%
FY17
GMED 12.7%
RVTY 4.4%
FY18
GMED 16.6%
RVTY 6.9%
FY19
GMED 14.5%
RVTY 7.7%
FY20
GMED 8.3%
RVTY 13.6%
FY21
GMED 12.0%
RVTY 11.0%
FY22
GMED 13.2%
RVTY 5.1%
FY23
GMED 3.7%
RVTY 2.7%
FY24
GMED 3.7%
RVTY 3.1%
FY25
GMED 11.0%
RVTY 3.3%
GMED
RVTY
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.